Nektar Therapeutics (NASDAQ:NKTR) Given Average Recommendation of “Hold” by Analysts

Nektar Therapeutics (NASDAQ:NKTR) has earned a consensus rating of “Hold” from the twenty-two ratings firms that are covering the company, Marketbeat reports. One analyst has rated the stock with a sell rating, nine have given a hold rating and eleven have assigned a buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $31.18.

A number of analysts have weighed in on NKTR shares. BTIG Research cut their target price on shares of Nektar Therapeutics from $101.00 to $80.00 and set a “buy” rating on the stock in a research report on Friday, February 28th. Zacks Investment Research downgraded Nektar Therapeutics from a “buy” rating to a “hold” rating and set a $21.00 price objective on the stock. in a report on Wednesday, April 15th. HC Wainwright lowered their target price on Nektar Therapeutics from $32.00 to $26.00 and set a “neutral” rating for the company in a report on Tuesday, May 12th. Piper Sandler reiterated a “buy” rating and issued a $35.00 target price on shares of Nektar Therapeutics in a research report on Friday, February 28th. Finally, Mizuho initiated coverage on Nektar Therapeutics in a research note on Tuesday, May 26th. They issued a “buy” rating and a $35.00 price objective for the company.

In other Nektar Therapeutics news, Director Robert Chess sold 8,000 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $18.38, for a total transaction of $147,040.00. Following the completion of the sale, the director now directly owns 284,973 shares in the company, valued at approximately $5,237,803.74. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 2.99% of the company’s stock.

A number of hedge funds have recently modified their holdings of NKTR. Canada Pension Plan Investment Board acquired a new position in Nektar Therapeutics in the first quarter valued at approximately $44,000. Advisory Services Network LLC increased its stake in shares of Nektar Therapeutics by 1,325.3% in the 4th quarter. Advisory Services Network LLC now owns 2,138 shares of the biopharmaceutical company’s stock valued at $47,000 after acquiring an additional 1,988 shares in the last quarter. Aigen Investment Management LP acquired a new position in shares of Nektar Therapeutics during the 1st quarter valued at $64,000. NewSquare Capital LLC bought a new position in Nektar Therapeutics during the first quarter worth $71,000. Finally, Dupont Capital Management Corp bought a new position in Nektar Therapeutics during the first quarter worth $80,000. Institutional investors and hedge funds own 98.20% of the company’s stock.

Nektar Therapeutics stock traded down $0.44 during midday trading on Friday, reaching $22.05. The company’s stock had a trading volume of 1,342,125 shares, compared to its average volume of 1,250,463. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.75 and a current ratio of 3.79. Nektar Therapeutics has a 52 week low of $13.63 and a 52 week high of $36.85. The business has a 50-day moving average price of $22.02 and a 200-day moving average price of $20.83.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings results on Thursday, May 7th. The biopharmaceutical company reported ($0.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.77) by $0.24. The company had revenue of $50.57 million for the quarter, compared to the consensus estimate of $46.88 million. Nektar Therapeutics had a negative net margin of 335.50% and a negative return on equity of 28.83%. The firm’s quarterly revenue was up 79.2% compared to the same quarter last year. During the same period last year, the company posted ($0.68) EPS. As a group, analysts expect that Nektar Therapeutics will post -2.55 earnings per share for the current fiscal year.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

Recommended Story: What is the Nikkei 225 index?    

Analyst Recommendations for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.